Logo

Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology

Share this

Lilly Presents Updated Data of Verzenio (abemaciclib) in P-III monarchE Trial Presented at ESMO and Published in the Annals of Oncology

Shots:

  • The P-III monarchE trial assessed Verzenio (150mg- bid) + SOC vs SOC alone in patients with EBC in a ratio (1:1) for 2yrs. Patients in both treatment arms were instructed to continue to receive adjuvant ET for up to 5-10 years as recommended by their clinician
  • In the updated analysis- the benefits of IDFS and DRFS were maintained. @3yrs; absolute improvement rates in IDFS and DRFS (5.4% and 4.2%). With additional follow up- the treatment benefit was maintained over time and extended beyond the 2yrs. treatment period
  • Consistent Verzenio treatment benefit in reducing the risk of recurrence was observed in patients regardless of Ki-67 score

Ref: Eli Lilly | Image: WRGB

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions